NO20004799L - Anvendelse av cabergolin ved behandling av urolig bensyndrom - Google Patents

Anvendelse av cabergolin ved behandling av urolig bensyndrom

Info

Publication number
NO20004799L
NO20004799L NO20004799A NO20004799A NO20004799L NO 20004799 L NO20004799 L NO 20004799L NO 20004799 A NO20004799 A NO 20004799A NO 20004799 A NO20004799 A NO 20004799A NO 20004799 L NO20004799 L NO 20004799L
Authority
NO
Norway
Prior art keywords
cabergoline
treatment
troubled
leg syndrome
syndrome
Prior art date
Application number
NO20004799A
Other languages
English (en)
Norwegian (no)
Other versions
NO20004799D0 (no
Inventor
Peter Schueler
Original Assignee
Upjohn Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Upjohn Co filed Critical Upjohn Co
Publication of NO20004799D0 publication Critical patent/NO20004799D0/no
Publication of NO20004799L publication Critical patent/NO20004799L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/48—Ergoline derivatives, e.g. lysergic acid, ergotamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/485—Morphinan derivatives, e.g. morphine, codeine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Emergency Medicine (AREA)
  • Anesthesiology (AREA)
  • Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
NO20004799A 1998-03-27 2000-09-26 Anvendelse av cabergolin ved behandling av urolig bensyndrom NO20004799L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US7963998P 1998-03-27 1998-03-27
PCT/US1999/004269 WO1999048484A2 (en) 1998-03-27 1999-03-24 Use of cabergoline in the treatment of restless legs syndrome

Publications (2)

Publication Number Publication Date
NO20004799D0 NO20004799D0 (no) 2000-09-26
NO20004799L true NO20004799L (no) 2000-10-11

Family

ID=22151836

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20004799A NO20004799L (no) 1998-03-27 2000-09-26 Anvendelse av cabergolin ved behandling av urolig bensyndrom

Country Status (23)

Country Link
US (1) US6114326A (es)
EP (1) EP1066038B1 (es)
JP (1) JP2002507562A (es)
KR (1) KR100597517B1 (es)
CN (1) CN1303286A (es)
AT (1) ATE313326T1 (es)
AU (1) AU747751B2 (es)
BR (1) BR9908953A (es)
CA (1) CA2320204A1 (es)
CZ (1) CZ297284B6 (es)
DE (1) DE69929041T2 (es)
DK (1) DK1066038T3 (es)
EA (1) EA002554B1 (es)
ES (1) ES2255255T3 (es)
HU (1) HUP0101954A3 (es)
IL (1) IL138522A0 (es)
NO (1) NO20004799L (es)
NZ (1) NZ507176A (es)
PL (1) PL343593A1 (es)
SK (1) SK13312000A3 (es)
TR (1) TR200002759T2 (es)
WO (1) WO1999048484A2 (es)
ZA (1) ZA200004452B (es)

Families Citing this family (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6375957B1 (en) 1997-12-22 2002-04-23 Euro-Celtique, S.A. Opioid agonist/opioid antagonist/acetaminophen combinations
DK1685839T3 (da) 1997-12-22 2013-06-24 Euro Celtique Sa Farmaceutisk oral doseringsform omfattende en kombination af en opioidagonist og opioidantagonist
US6477408B1 (en) * 2000-03-07 2002-11-05 Northwestern University Analysis of muscular activity in neonatal animals to screen for mutations and/or drugs that alter sleep and wake states
GB0007309D0 (en) 2000-03-24 2000-05-17 Pharmacia & Upjohn Spa Crystalline form V|| of cabergoline
GB0007308D0 (en) 2000-03-24 2000-05-17 Pharmacia & Upjohn Spa Process for preparing crystalline form | of cabergoline
US6426713B1 (en) * 2000-07-05 2002-07-30 Cirrus Logic, Inc. Independent control of calibration registers in a multi channel A-D converter
DE10053397A1 (de) * 2000-10-20 2002-05-02 Schering Ag Verwendung eines dopaminergen Wirkstoffes zur Behandlung von dopaminerg behandelbaren Erkrankungen
DE10043321B4 (de) * 2000-08-24 2005-07-28 Neurobiotec Gmbh Verwendung eines transdermalen therapeutischen Systems zur Behandlung der Parkinsonschen Krankheit, zur Behandlung und Prävention des prämenstruellen Syndroms und zur Lactationshemmung
AR031152A1 (es) * 2000-10-31 2003-09-10 Upjohn Co Tratamientos nuevos para el sindrome de piernas inquietas
DE10064453A1 (de) * 2000-12-16 2002-07-04 Schering Ag Verwendung eines dopaminergen Wirkstoffes zur Behandlung von dopaminerg behandelbaren Erkrankungen
US20020123503A1 (en) * 2000-12-21 2002-09-05 Malcolm Ross Cabergoline pharmaceutical compositions and methods of use thereof
CA2442423C (en) * 2001-03-30 2009-11-03 Toray Industries, Inc. Therapeutic drug for psychoneurotic disorders
CN1525851A (zh) 2001-05-11 2004-09-01 ������ҩ�����޹�˾ 抗滥用阿片样物质控释剂型
US20030134844A1 (en) * 2001-10-31 2003-07-17 Pfizer Inc. Nicontinic acetylcholine receptor antagonists in the treatment of restless legs syndrome
US20030176822A1 (en) * 2002-03-12 2003-09-18 Morgenlander Joel C. Method of treating restless leg syndrome
CA2478515C (en) * 2002-04-05 2010-09-28 Purdue Pharma Pharmaceutical preparation containing oxycodone and naloxone
US20040048779A1 (en) * 2002-05-06 2004-03-11 Erwin Schollmayer Use of rotigotine for treating the restless leg syndrome
DE60322067D1 (de) 2002-08-30 2008-08-21 Kyowa Hakko Kogyo Kk Adenosin-a2a-rezeptorantagonisten zur behandlung des syndroms der unruhigen beine oder nächtlichen myoklonus
WO2005027850A2 (en) 2003-09-17 2005-03-31 Xenoport, Inc. Treating or preventing restless legs syndrome using prodrugs of gaba analogs
WO2006079550A2 (en) * 2005-01-28 2006-08-03 Euro-Celtique S.A. Alcohol resistant dosage forms
EP1604666A1 (en) 2004-06-08 2005-12-14 Euro-Celtique S.A. Opioids for the treatment of the Chronic Obstructive Pulmonary Disease (COPD)
EP1604667A1 (en) * 2004-06-08 2005-12-14 Euro-Celtique S.A. Opioids for the treatment of the restless leg syndrome
KR20060030175A (ko) * 2004-10-05 2006-04-10 경북대학교 산학협력단 무정위성 운동 치료용 약학조성물
EP1695700A1 (en) * 2005-02-28 2006-08-30 Euro-Celtique S.A. Dosage form containing oxycodone and naloxone
EP1702558A1 (en) 2005-02-28 2006-09-20 Euro-Celtique S.A. Method and device for the assessment of bowel function
EA019879B1 (ru) * 2005-12-29 2014-07-30 Лексикон Фармасьютикалз, Инк. Полициклические производные аминокислот, содержащая их фармацевтическая композиция и способ лечения, использующий эти производные
EP2007369A4 (en) * 2006-04-03 2009-07-01 Teva Pharma USE OF RASAGILINE FOR THE TREATMENT OF LEG SYNDROME WITHOUT REST
WO2008046149A1 (en) * 2006-10-17 2008-04-24 Biologic Health Solutions Pty Ltd Herbal compositions for the prevention or treatment of restless leg syndrome
EP1952813A1 (en) * 2007-02-01 2008-08-06 Ferring International Center S.A. Medicament for the treatment of endometriosis
US7939665B2 (en) 2007-05-04 2011-05-10 Apotex Pharmachem Inc. Efficient process for the preparation of cabergoline and its intermediates
EP1987815A1 (en) * 2007-05-04 2008-11-05 Schwarz Pharma Ag Oronasopharyngeally deliverable pharmaceutical compositions of dopamine agonists for the prevention and/or treatment of restless limb disorders
EP2083008A1 (en) * 2007-12-07 2009-07-29 Axxonis Pharma AG Ergoline derivatives as selective radical scavengers for neurons
WO2010103039A1 (en) 2009-03-10 2010-09-16 Euro-Celtique S.A. Immediate release pharmaceutical compositions comprising oxycodone and naloxone
KR102023255B1 (ko) 2009-04-01 2019-09-19 바이알 - 포르텔라 앤드 씨에이 에스에이 니트로카테콜 유도체를 포함하는 제약 제제 및 그의 제조 방법
US8690933B2 (en) * 2009-08-31 2014-04-08 Brigham Young University System and method for treating symptoms of restless legs syndrome
US20140045900A1 (en) 2011-02-11 2014-02-13 Bial-Portela & Ca, S.A. Administration regime for nitrocatechols
KR20180037074A (ko) 2013-07-23 2018-04-10 유로-셀티큐 에스.에이. 장내 세균총이상을 초래하고/하거나 장내 박테리아 전위에 대한 위험을 증가시키는 질환과 통증으로 인해 고통받고 있는 환자에서 통증을 치료하는데 사용하기 위한 옥시코돈과 날록손의 조합물
PL232974B1 (pl) * 2015-12-09 2019-08-30 Ofta Spolka Z Ograniczona Odpowiedzialnoscia Zastosowanie agonistów receptorów dopaminergicznych typu 2 w leczeniu schorzeń oczu wywołanych przez podwyższony poziom śródbłonkopochodnego czynnika wzrostu naczyń
WO2018129351A1 (en) 2017-01-05 2018-07-12 Shriram Raghunathan Restless leg syndrome or overactive nerve treatment
US11103691B2 (en) 2019-10-03 2021-08-31 Noctrix Health, Inc. Peripheral nerve stimulation for restless legs syndrome
AU2020358093B2 (en) 2019-10-03 2025-10-23 Noctrix Health, Inc. Peripheral nerve stimulation for restless legs syndrome

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4526892A (en) * 1981-03-03 1985-07-02 Farmitalia Carlo Erba, S.P.A. Dimethylaminoalkyl-3-(ergoline-8'βcarbonyl)-ureas
US5496836A (en) * 1994-05-05 1996-03-05 Mount Sinai School Of Medicine Of The City University Of New York Use of famotidine and related compounds in the treatment of movement disorders

Also Published As

Publication number Publication date
TR200002759T2 (tr) 2001-02-21
ES2255255T3 (es) 2006-06-16
AU747751B2 (en) 2002-05-23
HUP0101954A2 (hu) 2001-12-28
CN1303286A (zh) 2001-07-11
CZ20003419A3 (cs) 2002-01-16
EP1066038B1 (en) 2005-12-21
ZA200004452B (en) 2002-02-27
CZ297284B6 (cs) 2006-10-11
ATE313326T1 (de) 2006-01-15
PL343593A1 (en) 2001-08-27
BR9908953A (pt) 2000-12-05
CA2320204A1 (en) 1999-09-30
IL138522A0 (en) 2001-10-31
EP1066038A2 (en) 2001-01-10
KR20010052222A (ko) 2001-06-25
DK1066038T3 (da) 2006-04-24
KR100597517B1 (ko) 2006-07-10
EA200000994A1 (ru) 2001-02-26
AU3353199A (en) 1999-10-18
DE69929041T2 (de) 2006-07-20
US6114326A (en) 2000-09-05
WO1999048484A3 (en) 1999-11-25
WO1999048484A2 (en) 1999-09-30
DE69929041D1 (de) 2006-01-26
JP2002507562A (ja) 2002-03-12
NZ507176A (en) 2003-09-26
EA002554B1 (ru) 2002-06-27
SK13312000A3 (sk) 2001-05-10
HUP0101954A3 (en) 2002-09-30
NO20004799D0 (no) 2000-09-26

Similar Documents

Publication Publication Date Title
NO20004799D0 (no) Anvendelse av cabergolin ved behandling av urolig bensyndrom
MXPA03003912A (es) Tratamientos nuevos para el sindrome de piernas inquietas.
ATE424413T1 (de) Analoge des glucagon-ähnlichen peptids-1
DE60005810D1 (de) Fussstütze und möbelstück
DK1039912T3 (da) Angiostatiske midler og præparater til behandling af GLC1A-glaukom
DK0755249T3 (da) Anvendelse af Maillard-reaktionsinhibitor til behandling af amyloidose-baseret sygdom
IS5280A (is) Samsetningar til meðhöndlunar og fyrirbyggingar ásegamyndun í slagæð og notkun á þætti Xa lata einum sér og/eða í samsetningu með miðli gegn blóðflöguþyrpingu
NO994778L (no) Fremgangsmåter og preparater for behandling av inflammatorisk tarmsyndrom
NO20031860D0 (no) Kahalaolid F
NO993360L (no) Anvendelse av pramipeksol ved behandling av "restless leg"- syndromet
AU3922900A (en) Use of (valeriana) for the treatment of restless leg syndrome and related disorders
SE0302361D0 (sv) Inhibering av upptagning av monoamin
NO20005548D0 (no) Mykobakterieinhibitorer
GEP20074097B (en) Use of specific dose of fondaparinux sodium for the treatment of acs
ITTS980014A3 (it) Sedia monogamba
NO964545A (no) Protese omfattende leggdel, kalsojdel og fotdel
UA33864A (uk) Кардіотонічний засіб суфан у вигляді супозиторіїв
MXPA01010449A (es) Composicion y metodo util para el tratamiento del colico.
IT1309840B1 (it) Accessorio per il sostegno di calzini, gambaletti, calze e manufattianaloghi anche se privi di elastico.
KR980000461U (ko) 탁자다리
KR970048882U (ko) 테이블 다리
ITPD990199A1 (it) Tavolo da gioco e procedimento di gioco preferito
ITTS980017V0 (it) Sedia monogamba
ITMI20001967A0 (it) Gambaletto per medicazione, particolarmente per ulcere della gamba e simili.
MX9101325A (es) Composicion para regeneracion celular para el tratamiento de quemaduras con accion desinflamatoria

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application